RAPT Therapeutics, a pioneering clinical stage immunology-based therapeutics company, is thrilled to announce its successful funding round, raising an impressive $150 million. This significant capital injection will enable RAPT to accelerate the development of its promising oral small molecule therapies targeting unmet medical needs in inflammatory diseases and oncology. With a robust proprietary discovery and development engine, RAPT is advancing two unique drug candidates鈥擱PT193 and FLX475鈥攕pecifically designed to modulate critical immune drivers by targeting the C-C motif chemokine receptor 4 (CCR4). RPT193 is aimed at addressing inflammation, while FLX475 is positioned as a groundbreaking approach for cancer treatment. The funding will not only bolster these ongoing trials but also allow RAPT to expand its pipeline by pursuing additional targets currently in the discovery stage. As the company sets its sights on delivering innovative therapies to patients who desperately need them, this funding marks a pivotal moment in RAPT's journey, demonstrating confidence in its groundbreaking science and commitment to transforming the landscape of immunology and oncology therapeutics. With a passionate team and a clear vision, RAPT Therapeutics is poised to make a lasting impact in the fight against these complex diseases.
RAPT Therapeutics Raises $150 Million in Funding to Advance Innovative Immunology Therapies
Recently funded 路 $150.0MBiopharmaceutical
Get the full RAPT company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
